ClearPoint Neuro (NASDAQ:CLPT) Releases Quarterly Earnings Results, Misses Expectations By $0.05 EPS

ClearPoint Neuro (NASDAQ:CLPT) issued its quarterly earnings data on Wednesday. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.05), Zacks reports. ClearPoint Neuro had a negative return on equity of 62.10% and a negative net margin of 59.64%. ClearPoint Neuro updated its FY 2025 guidance to EPS.

ClearPoint Neuro Stock Up 3.0 %

NASDAQ:CLPT traded up $0.50 during trading hours on Wednesday, reaching $17.22. 239,202 shares of the company’s stock were exchanged, compared to its average volume of 204,522. ClearPoint Neuro has a 1-year low of $5.11 and a 1-year high of $19.22. The firm has a market capitalization of $475.01 million, a price-to-earnings ratio of -24.96 and a beta of 1.03. The company has a 50-day moving average of $16.62 and a 200 day moving average of $13.78.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on CLPT. B. Riley boosted their price target on shares of ClearPoint Neuro from $15.00 to $20.00 and gave the company a “buy” rating in a research report on Tuesday, January 28th. Lake Street Capital boosted their target price on ClearPoint Neuro from $17.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday, January 21st.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.